Portrait of Dr. Sultan Almudimeegh

Research team

Dr. Sultan Almudimeegh

MSc, PhD  ·  Assistant Professor of Pharmacology and Toxicology


College of Pharmacy, King Saud University, Riyadh 11451
Office 1B34 — Lab 1B-68, Building 23
salmudimeegh@ksu.edu.sa  ·  ORCID 0009-0002-4192-4034

Background

Professional Summary

Dr. Almudimeegh completed his PhD in 2022 at University College London under the supervision of Professor Kirsten Harvey. His doctoral research focused on the inflammatory role of LRRK2 in Parkinson’s disease, contributing to a deeper understanding of neuroinflammation in neurodegenerative disorders. He also investigated key signalling pathways in Down syndrome and the molecular basis of hyperekplexia syndrome, with findings published in high-impact journals.

Since joining King Saud University he has broadened his work in two directions: the biology of cancer and aging, including senescence and nanoparticle toxicology; and botulinum neurotoxins, approached through both computational discovery and forensic toxicology. He also works at the intersection of artificial intelligence and regulatory science, developing methods that apply language models to the review of nonclinical evidence.

He is technically proficient in cellular and transgenic animal models, with hands-on experience across biological, biochemical and proteomic tools: live-cell and lysate-based luciferase assays, real-time PCR, western blotting, in vivo bioluminescent imaging, molecular cloning and plasmid preparation.

Research Interests

  • Botulinum neurotoxins — molecular pathogenesis, countermeasures and forensic differentiation
  • Neuroinflammation and neuroimmune signalling in neurodegenerative disease
  • Autophagy, cellular senescence and aging-related pathways
  • Computational drug discovery and structure-guided screening
  • Artificial intelligence applied to regulatory science and nonclinical evidence review
  • Nanoparticle toxicology and immune modulation

Research Goals

  • Elucidate the molecular links between inflammation, neurodegeneration and aging, with a focus on LRRK2 and senescence pathways
  • Advance the understanding of botulinum neurotoxin pathogenesis and support the development of countermeasures and detection methods
  • Translate cellular and genetic insight into interventions for neurological and inflammatory disorders
  • Build computational and AI-based methods that make nonclinical and regulatory evidence review faster and more reliable

Active now

Current Projects

Neurodegeneration

Investigating the role of LRRK2 in linking autophagy and cellular senescence in neurodegeneration.

Cancer and senescence

Therapy-induced senescence as a cell-fate switch in colon cancer, using isogenic HCT116 models, and senolytic compounds as potential cancer therapeutics.

Botulinum neurotoxins

Molecular pathogenesis and emerging countermeasures, and a toxicological framework for distinguishing accidental from intentional botulism.

AI and regulatory science

Large language model–assisted screening of nonclinical data for cell and gene therapies.

Computational discovery

Immunoinformatics and reverse-vaccinology approaches to antigen design, including a multi-epitope vaccine candidate against Borrelia burgdorferi.

Supervision

Currently supervising master’s projects in regulatory science and forensic toxicology, alongside PharmD research students.

Selected Publications

For a complete list, see ORCID.

  • Almudimeegh S, et al. Botulinum neurotoxin: from molecular pathogenesis to emerging countermeasures. Saudi Pharm J. 2026. doi:10.1007/s44446-026-00090-2
  • Alshamrani AA, Bin Salman SB, Alsaleh NB, Assiri MA, Almutairi MM, Almudimeegh S, Alwhaibi A, As Sobeai HM. miRNA-driven sensitization of breast cancer cells to Doxorubicin treatment following exposure to low dose of Zinc Oxide nanoparticles. Saudi Pharm J. 2024;32(11):102169. doi:10.1016/j.jsps.2024.102169
  • Alsaleh NB, Aljarbou AM, Assal ME, Assiri MA, Almutairi MM, As Sobeai HM, Alshamrani AA, Almudimeegh S, Hatshan MR, Adil SF. Synthesis, Characterization, and Toxicity Assessment of Zinc Oxide-Doped Manganese Oxide Nanoparticles in a Macrophage Model. Pharmaceuticals. 2024;17(2):168. doi:10.3390/ph17020168
  • Alsaleh NB, Assiri MA, Aljarbou AM, Almutairi MM, As Sobeai HM, Alshamrani AA, Almudimeegh S. Adverse Responses following Exposure to Subtoxic Concentrations of Zinc Oxide and Nickle Oxide Nanoparticles in the Raw 264.7 Cells. Toxics. 2023;11(8):674. doi:10.3390/toxics11080674
  • Al-Harbi NO, Imam F, Al-Harbi MM, Qamar W, Aljerian K, Khalid Anwer M, Alharbi M, Almudimeegh S, Alhamed AS, Alshamrani AA. Effect of Apremilast on LPS-induced immunomodulation and inflammation via activation of Nrf2/HO-1 pathways in rat lungs. Saudi Pharm J. 2023;31(7):1327-1338. doi:10.1016/j.jsps.2023.05.022
  • Alghibiwi H, Ansari MA, Nadeem A, Algonaiah MA, Attia SM, Bakheet SA, Albekairi TH, Almudimeegh S, Alhamed AS, Shahid M, Alwetaid MY, Alassmrry YA, Ahmad SF. DAPTA, a C-C Chemokine Receptor 5 (CCR5), Leads to the Downregulation of Notch/NF-κB Signaling and Proinflammatory Mediators in CD40(+) Cells in Experimental Autoimmune Encephalomyelitis Model in SJL/J Mice. Biomedicines. 2023;11(6):1511. doi:10.3390/biomedicines11061511
  • Alomar HA, Nadeem A, Ansari MA, Attia SM, Bakheet SA, Al-Mazroua HA, Alhazzani K, Assiri MA, Alqinyah M, Almudimeegh S, Ahmad SF. Mitogen-activated protein kinase inhibitor PD98059 improves neuroimmune dysfunction in experimental autoimmune encephalomyelitis in SJL/J mice through the inhibition of nuclear factor-kappa B signaling in B cells. Brain Res Bull. 2023;194:45-53. doi:10.1016/j.brainresbull.2023.01.003
  • Aboheimed GI, AlRasheed MM, Almudimeegh S, Peña-Guerra KA, Cardona-Londoño KJ, Salih MA, Seidahmed MZ, Al-Mohanna F, Colak D, Harvey RJ, Harvey K, Arold ST, Kaya N, Ruiz AJ. Clinical, genetic, and functional characterization of the glycine receptor β-subunit A455P variant in a family affected by hyperekplexia syndrome. J Biol Chem. 2022;298(7):102018. doi:10.1016/j.jbc.2022.102018
  • Granno S, Nixon-Abell J, Berwick DC, Tosh J, Heaton G, Almudimeegh S, Nagda Z, Rain JC, Zanda M, Plagnol V, Tybulewicz VLJ, Cleverley K, Wiseman FK, Fisher EMC, Harvey K. Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus. Sci Rep. 2019;9(1):7322. doi:10.1038/s41598-019-43820-4